HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Cu Nguyen Selected Research

Poly A

1/2021A comprehensive map of alternative polyadenylation in African American and European American lung cancer patients.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Cu Nguyen Research Topics

Disease

15Neoplasms (Cancer)
01/2024 - 05/2004
3Disease Progression
01/2024 - 05/2004
3Colonic Neoplasms (Colon Cancer)
09/2005 - 08/2004
3Asthma (Bronchial Asthma)
11/2003 - 11/2002
2Alzheimer Disease (Alzheimer's Disease)
01/2024 - 08/2005
2BCR-ABL Positive Chronic Myelogenous Leukemia (Chronic Myelogenous Leukemia)
01/2024 - 02/2011
2Fibrosis (Cirrhosis)
01/2024 - 08/2010
2Acute Myeloid Leukemia (Acute Myelogenous Leukemia)
01/2023 - 01/2020
2Lung Neoplasms (Lung Cancer)
01/2021 - 12/2016
2Pulmonary Fibrosis (Fibrosing Alveolitis)
03/2012 - 08/2010
2Inflammation (Inflammations)
02/2003 - 11/2002
1Glioblastoma (Glioblastoma Multiforme)
01/2024
1Glioma (Gliomas)
01/2024
1Leukemia
01/2024
1Neurodegenerative Diseases (Neurodegenerative Disease)
01/2024
1Cognitive Dysfunction
01/2024
1Chromosome Aberrations (Chromosome Abnormalities)
01/2021
1Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
01/2021
1Breast Neoplasms (Breast Cancer)
01/2021
1Aneuploidy (Aneuploid)
01/2021
1Triple Negative Breast Neoplasms
12/2018
1Pancreatic Neoplasms (Pancreatic Cancer)
03/2018
1Carcinogenesis
03/2018
1Adenocarcinoma
03/2018
1Anaplasia
11/2016
1Infarction (Infarctions)
01/2013
1Colorectal Neoplasms (Colorectal Cancer)
05/2009
1Carcinoma (Carcinomatosis)
08/2004
1Adenomatous Polyposis Coli (Familial Adenomatous Polyposis)
08/2004
1Hypertension (High Blood Pressure)
05/2004
1Edema (Dropsy)
02/2003
1Eosinophilia
11/2002

Drug/Important Bio-Agent (IBA)

9ICG 001IBA
01/2024 - 08/2004
8CateninsIBA
01/2024 - 02/2011
6beta CateninIBA
01/2024 - 08/2004
5MicroRNAs (MicroRNA)IBA
01/2021 - 02/2015
4SurvivinIBA
01/2024 - 05/2005
4DNA (Deoxyribonucleic Acid)IBA
01/2021 - 12/2016
3Messenger RNA (mRNA)IBA
01/2021 - 10/2017
2CREB-Binding ProteinIBA
01/2024 - 08/2010
2RNA (Ribonucleic Acid)IBA
01/2021 - 01/2020
2Cyclic AMP Response Element-Binding Protein (Cyclic AMP-Responsive DNA-Binding Protein)IBA
03/2018 - 08/2010
2Carrier Proteins (Binding Protein)IBA
03/2018 - 08/2010
2Proteins (Proteins, Gene)FDA Link
11/2016 - 05/2005
2NucleotidesIBA
02/2015 - 05/2004
2TCF Transcription FactorsIBA
08/2010 - 08/2005
2NF-kappa B (NF-kB)IBA
02/2003 - 11/2002
2Transcription Factor AP-1 (Transcription Factor AP 1)IBA
02/2003 - 11/2002
1Imatinib Mesylate (Gleevec)FDA Link
01/2024
1Chimeric Antigen ReceptorsIBA
01/2024
1Small Cytoplasmic RNAIBA
01/2024
1Cytostatic AgentsIBA
01/2024
1ProdrugsIBA
01/2024
1AntigensIBA
01/2024
1CohesinsIBA
01/2023
13' Untranslated Regions (3' UTR)IBA
01/2021
1Formaldehyde (Formol)FDA Link
01/2021
1ParaffinIBA
01/2021
1Poly AIBA
01/2021
1Untranslated RNA (Noncoding RNA)IBA
01/2021
1GemcitabineFDA Link
03/2018
1CollagenIBA
03/2012
1gamma Catenin (Plakoglobin)IBA
02/2011
1Bleomycin (Blenoxane)FDA LinkGeneric
08/2010
1LigandsIBA
05/2009
1Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/2009
1Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA
05/2009
1Cyclin D1IBA
09/2005
1Nerve Growth Factor (NGF)IBA
08/2005
1Oxidoreductases (Dehydrogenase)IBA
11/2003
1Transcription Factors (Transcription Factor)IBA
02/2003
1PNRI299IBA
02/2003
1Interleukin-4 (Interleukin 4)IBA
02/2003
1AntioxidantsIBA
11/2002
1MOL 294IBA
11/2002
1Oxidants (Oxidizing Agents)IBA
11/2002
1Interleukin-13IBA
11/2002

Therapy/Procedure

5Therapeutics
01/2024 - 03/2018
2Drug Therapy (Chemotherapy)
01/2024 - 12/2018
1Immunotherapy
01/2024
1Decompression
01/2024
1Aftercare (After-Treatment)
01/2024